How to sequence treatment in relapsed ovarian cancer

Research output: Contribution to journalArticlepeer-review


Numerous disease- and patient-related factors must be considered when selecting systemic therapy for recurrent ovarian cancer. Anti-angiogenics (bevacizumab) and poly(ADP-ribose) polymerase inhibitors (olaparib, niraparib and rucaparib) have an important role as maintenance of platinum-based chemotherapy for recurrent disease and their use in the first-line setting of advanced-stage disease is becoming established. As previous exposure to none, one or both of these drug classes is integral to selecting next therapy, front-line use impacts on options available to treat recurrent disease. A key strategy to delay platinum resistance and improve prognosis of recurrent disease is to alternate treatments with different mechanisms of action. The multiple mechanisms of trabectedin and its complementarity with platinum allow intercalation between platinum regimens in potentially platinum-responsive patients with recurrent disease. Sandro Pignata and Sabrina Chiara Cecere.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalFuture Oncology
Issue number3s
Publication statusPublished - Jan 2021


  • antiangiogenics
  • ovarian cancer
  • PARP inhibitors
  • platinum-based chemotherapy
  • recurrent
  • trabectedin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'How to sequence treatment in relapsed ovarian cancer'. Together they form a unique fingerprint.

Cite this